LivaNova PLC LIVN R2K

Healthcare · Medical Devices · United Kingdom

https://www.livanova.com

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Market & Price

Market Cap

$4.05B

Current Price

$73.80

High / Low (52W)

$75.42 / $41.13

Beta

0.82

Valuation

Stock P/E

37.65

Industry PE

23.65

Forward P/E

15.94

PEG Ratio

0.84

Book Value

$22.06

Price to Book

3.34

P/S

2.83

EV/EBITDA

14.70

Dividend Yield

Profitability & Returns

ROCE

-9.54%

ROE

9.54%

ROA

5.27%

Profit Margin

7.47%

Op Margin

14.39%

EPS (Latest Qtr)

$0.40

EPS (TTM)

$1.96

Balance Sheet & Liquidity

Debt/Equity

0.28

Quick Ratio

1.01

Current Ratio

1.33

Debt

$343.44M

Total Assets

$2.61B

Current Assets

$1.10B

Working Capital

$293.54M

Ownership

Promoter Holding

0.36%

Chg in Prom Hold

FII / Inst Holding

112.28%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$3.86B

Total Revenue (TTM)

$1.43B

EBITDA

$262.49M

Free Cash Flow

$198.05M

Operating Cash Flow

$245.59M

Shares Outstanding

54.93M

Gross Margin

67.86%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

10.75%

Profit 5Y

-60.38%

Revenue (YoY)

14.30%

Earnings (YoY)

PROS

Compounding revenue at 10.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -60.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LIVN LivaNova PLC R2K	73.80	37.65	$4.05B	-	-9.54%	9.54%	10.75%	-60.38%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2016	Jun 2016	Sep 2016	Oct 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	226.82M	255.84M	251.25M	278.36M	250.40M	287.50M	272.08M	296.98M	250.80M	277.17M	268.61M	287.59M	242.40M	182.21M	240.08M	269.56M	247.60M	264.48M	253.22M	270.06M	240.18M	254.15M	252.60M	263.42M	293.88M	286.11M	294.91M	318.57M	318.12M	-	316.86M	352.52M	357.75M	360.92M	362.26M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100.60M	113.54M	112.90M	121.15M	118.51M
Gross Profit	131.73M	148.45M	153.90M	57.98M	125.42M	147.65M	170.10M	161.86M	172.23M	162.09M	193.96M	174.35M	204.07M	163.60M	197.11M	179.41M	204.64M	165.31M	114.97M	147.59M	166.90M	163.41M	172.28M	168.66M	201.64M	168.44M	184.35M	170.92M	174.08M	205.20M	201.80M	203.21M	214.88M	221.03M	-	216.25M	238.99M	244.85M	239.77M	243.75M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	167.64M	184.81M	190.84M	197.19M	202.28M
Operating Income	-9.07M	25.02M	30.37M	-	-14.88M	19.75M	27.77M	30.02M	18.94M	12.53M	21.61M	-5.76M	-276.45M	-20.78M	-29.88M	25.76M	-143.98M	-581.00K	-16.74M	-7.55M	-249.02M	-5.70M	-36.26M	16.42M	24.75M	9.51M	31.76M	-131.97M	-2.34M	17.38M	4.46M	16.25M	40.17M	35.62M	-	48.62M	54.18M	54.01M	42.58M	41.47M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-285.69M	60.64M	59.99M	53.20M	51.37M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.29M	12.28M	10.86M	10.86M	8.29M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-315.65M	33.32M	33.91M	27.63M	27.48M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.66M	6.15M	7.11M	-3.28M	4.34M
Net Income	-40.38M	8.96M	-1.57M	-25.09M	-29.80M	11.27M	47.50M	27.83M	-111.69M	13.27M	15.07M	-7.18M	-210.56M	-14.85M	-29.21M	32.12M	-143.23M	36.46M	-89.42M	-14.81M	-281.05M	-30.76M	-56.49M	-43.44M	-5.13M	2.99M	16.44M	-107.34M	7.37M	1.16M	-7.32M	-41.94M	16.33M	32.95M	-	-327.32M	27.16M	26.78M	30.91M	22.29M
Diluted EPS	-0.83	0.18	-0.03	-0.96	-0.61	0.23	0.98	0.57	-2.32	0.27	0.31	-0.15	-4.34	-0.31	-0.60	0.66	-2.96	0.75	-1.84	-0.30	-5.78	-0.63	-1.15	-0.84	-0.10	0.06	0.30	-2.01	0.14	0.02	-0.14	-0.78	0.30	0.60	-	-6.01	0.50	0.49	0.56	0.40
R&D Expense	31.69M	30.21M	32.17M	-	-	20.39M	33.83M	22.90M	-	31.75M	34.22M	42.42M	-	43.58M	34.54M	45.90M	-	35.90M	25.15M	47.37M	-	44.62M	52.56M	42.13M	-	40.92M	34.23M	35.73M	49.99M	51.12M	46.54M	45.66M	44.74M	48.80M	-	37.88M	47.19M	48.58M	-	58.70M

Profit & Loss (Annual)

Figures in USD.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	964.86M	1.01B	1.11B	1.08B	934.24M	-	1.02B	1.15B	1.25B	1.39B
Cost of Revenue	-	-	-	-	-	-	-	-	314.58M	397.73M	399.95M	448.18M
Gross Profit	254.66M	264.25M	559.51M	651.62M	-	723.80M	594.76M	-	707.23M	755.82M	853.48M	939.87M
Operating Expenses	-	-	-	-	-	-	-	-	654.58M	734.34M	724.43M	740.48M
Operating Income	80.01M	88.65M	33.45M	96.49M	-248.07M	-171.55M	-273.90M	-	52.64M	21.48M	129.05M	199.39M
EBITDA	-	-	-	-	-	-	-	-	30.90M	38.48M	202.52M	-111.86M
Interest Expense	-	-	-	-	-	-	-	-	48.25M	58.85M	63.07M	49.29M
Pretax Income	-	-	-	-	-	-	-	-	-75.14M	-81.23M	88.31M	-220.78M
Tax Provision	-	-	-	-	-	-	-	-	11.05M	-98.88M	25.06M	21.64M
Net Income	54.89M	57.85M	-62.79M	-25.09M	-189.40M	-157.64M	-348.82M	-	-86.25M	17.55M	63.23M	-242.47M
Diluted EPS	2.00	2.17	-1.28	-0.52	-3.91	-3.26	-7.18	-	-1.61	0.32	1.16	-4.45
R&D Expense	45.22M	42.24M	82.08M	109.52M	145.95M	146.85M	152.90M	183.41M	155.81M	193.82M	182.51M	185.76M

Compounded Sales Growth

5 Years:	10.75%
1 Year:	14.30%

Compounded Profit Growth

5 Years:	-60.38%
1 Year:	-

Stock Price Performance

1 Year:	+70.64%
6 Months:	+16.57%
3 Months:	+4.53%
1 Month:	+25.25%

Balance Sheet (Annual)

Figures in USD.

Metric	Apr 2013	Apr 2014	Apr 2015	Oct 2015	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	315.94M	-	2.56B	2.34B	2.50B	2.55B	2.41B	2.40B	-	2.29B	2.43B	2.51B	2.61B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	886.14M	988.16M	1.13B	1.10B
Cash & Equivalents	103.30M	124.19M	124.19M	-	112.61M	39.79M	93.61M	47.20M	61.14M	252.83M	-	214.17M	266.50M	428.86M	635.55M
Inventory	-	-	-	-	-	-	-	-	-	-	-	129.38M	147.89M	147.57M	164.70M
Receivables	-	-	-	-	-	-	-	-	-	-	-	183.11M	215.07M	193.16M	215.99M
Total Liabilities	-	-	39.37M	-	747.28M	635.72M	688.58M	1.05B	1.03B	1.29B	-	1.09B	1.15B	1.19B	1.41B
Current Liabilities	-	-	31.45M	-	359.12M	349.89M	406.02M	496.75M	512.55M	309.05M	-	297.40M	334.98M	392.12M	808.07M
Long Term Debt	-	-	0	-	91.79M	75.22M	61.96M	139.54M	260.33M	642.30M	-	518.07M	568.54M	549.62M	345.19M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	580.43M	640.40M	676.77M	433.77M
Total Equity	229.57M	259.10M	276.57M	74.43M	1.81B	1.71B	1.82B	1.50B	1.38B	1.11B	-	1.21B	1.28B	1.32B	1.20B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	53.85M	53.94M	54.44M	55.54M

Cash Flows (Annual)

Figures in USD.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	54.20M	79.68M	90.15M	91.34M	120.49M	-91.14M	-79.42M	-	69.92M	74.91M	183.04M	254.34M
Investing Cash Flow	-34.41M	-9.77M	-44.52M	-52.85M	-120.56M	-41.29M	-41.84M	-	-38.41M	-40.33M	-48.16M	-72.91M
Financing Cash Flow	-37.27M	-48.26M	-118.04M	11.29M	-42.35M	146.58M	310.76M	-	280.13M	21.48M	18.55M	-285.66M
Capital Expenditure	-15.22M	-6.69M	-38.36M	-32.93M	-37.19M	-24.69M	-35.02M	-	-26.52M	-34.98M	-47.11M	-81.05M
Free Cash Flow	38.97M	72.99M	51.79M	58.41M	83.30M	-115.83M	-114.45M	-	43.40M	39.93M	135.93M	173.29M
Net Change in Cash	-	-	-	-	-	-	-	-	311.64M	56.07M	153.43M	-104.23M
Share Buybacks	72.36M	55.02M	54.49M	0	50.00M	0	0	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Apr 2014	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	58.0%	64.4%	-	66.8%	63.7%	-	69.2%	65.5%	68.1%	67.7%
Operating Margin %	-	-	3.5%	9.5%	-22.4%	-15.8%	-29.3%	-	5.2%	1.9%	10.3%	14.4%
Net Margin %	-	-	-6.5%	-2.5%	-17.1%	-14.5%	-37.3%	-	-8.4%	1.5%	5.0%	-17.5%
ROE %	21.2%	20.9%	-3.7%	-1.4%	-12.6%	-11.4%	-31.4%	-	-7.1%	1.4%	4.8%	-20.2%
ROCE %	-	31.2%	1.7%	4.6%	-12.1%	-9.0%	-13.1%	-	2.6%	1.0%	6.1%	11.1%

Shareholding Pattern

Insiders

0.36%

Institutions

112.28%

Public Float

112.69%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	13.00%	7.14M	$526.85M
2	Primecap Management Company	7.66%	4.21M	$310.48M
3	FMR, LLC	4.85%	2.67M	$196.80M
4	AQR Capital Management, LLC	4.54%	2.49M	$184.08M
5	Millennium Management Llc	4.44%	2.44M	$179.97M
6	Artisan Partners Limited Partnership	3.86%	2.12M	$156.66M
7	State Street Corporation	3.77%	2.07M	$152.96M
8	Wellington Management Group, LLP	3.44%	1.89M	$139.53M
9	Dimensional Fund Advisors LP	3.32%	1.83M	$134.78M
10	American Century Companies Inc	3.27%	1.79M	$132.47M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LIVN

No recent headlines available.

LIVN · Healthcare

LivaNova PLC

About

Key Facts

Sector	Healthcare
Industry	Medical Devices
Headquarters	United Kingdom
Employees	3,300
Website	https://www.livanova.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

LivaNova PLC LIVN R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More